Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and Nivolumab in Recurrent/Metastatic HNSCC
NCT03370276Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Dec 2017
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, KL-140 in head and neck squamous cell carcinoma (HNSCC), sponsored by Moffitt Cancer Center. Started Dec 2017; status: completed.
02
Drugs
nivolumabKL-140
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03370276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03370276.